Related Experiment Videos
[Hormonal contraceptives of differentiated composition -- effects on thrombocyte function (author's transl)]
Zentralblatt Fur Gynakologie
|January 1, 1981
Summary
Hormonal contraceptives may affect thrombocyte function and thromboblastographic values, potentially increasing thrombo-embolism risk. Further research is needed to confirm these findings in women using these medications.
Area of Science:
- Hematology
- Pharmacology
- Reproductive Health
Background:
- Compound hormonal contraceptives containing gestagens are widely used for birth control.
- Potential hematological side effects of hormonal contraceptives require thorough investigation.
Purpose of the Study:
- To investigate the effects of compound hormonal contraceptives on thrombocyte parameters and thromboblastographic values.
- To assess potential correlations between contraceptive composition and observed hematological changes.
Main Methods:
- Blood samples were collected from 62 women over six months.
- Platelet count, proliferation, aggregation, adhesiveness, and thromboblastographic values were measured.
- Participants used either a threefold or twofold gestagen-differentiated hormonal contraceptive.
Main Results:
- Significant deviations from normal values in thrombocyte function and thromboblastographic parameters were observed.
- Individual observations did not yield definitive conclusions.
- The type and concentration of oestrogens and gestagens showed minor influence on the observed changes.
Conclusions:
- Hormonal contraceptives are likely associated with thrombocyte function and thromboblastographic value alterations.
- A slightly elevated risk of thrombo-embolism should be considered in women using hormonal contraceptives, especially with co-existing risk factors.